Jiangsu Lianhuan Pharmaceutical (600513) Fundamentals 2026 — Revenue Analysis | SniperIQ
Jiangsu Lianhuan Pharmaceutical (600513) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥4.3B, trading at ¥15.06 on the SHH. This SniperIQ fundamentals page covers Jiangsu Lianhuan Pharmaceutical's valuation, profitability (net margin -4.0%), revenue (¥2.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jiangsu Lianhuan Pharmaceutical's market cap?
Jiangsu Lianhuan Pharmaceutical (600513) has a market capitalization of approximately ¥4.3B, trading at ¥15.06 on the SHH. Market cap moves with the live share price.
What is Jiangsu Lianhuan Pharmaceutical's P/E ratio?
Jiangsu Lianhuan Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jiangsu Lianhuan Pharmaceutical?
Jiangsu Lianhuan Pharmaceutical runs a net profit margin of -4.0%, a gross margin of 31.0%, and an operating margin of -1.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jiangsu Lianhuan Pharmaceutical generate?
Jiangsu Lianhuan Pharmaceutical reported revenue of ¥2.7B for fiscal year 2025, with net income of -¥98M and earnings per share (EPS) of -0.34. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jiangsu Lianhuan Pharmaceutical pay a dividend?
Jiangsu Lianhuan Pharmaceutical offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Jiangsu Lianhuan Pharmaceutical financially healthy?
Jiangsu Lianhuan Pharmaceutical carries a debt-to-equity ratio of 1.06x and a current ratio of 0.94x, with a market beta of -0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jiangsu Lianhuan Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jiangsu Lianhuan Pharmaceutical (600513) the key facts are: market cap ¥4.3B, revenue ¥2.7B, 52-week range 13.67-32.27. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jiangsu Lianhuan Pharmaceutical's full fundamentals live
Get Jiangsu Lianhuan Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.